Hepion Pharmaceuticals appoints Dr. Kaouthar Lbiati as interim CEO as it pivots to diagnostic tests for celiac, COVID, liver cancer and more.

In December, Hepion CEO and Director Robert Foster resigned from his positions for personal reasons and Chief Financial Officer John Cavan was appointed interim CEO.

In addition, Edison-based Hepion said CEO and Director Robert Foster resigned from his positions for personal reasons, effective immediately.

Hepion’s head honcho Robert Foster, Ph.D., has also resigned, citing personal reasons. Chief Financial Officer John Cavan has stepped up and will lead the biotech as interim CEO.

In addition, the Company announced that Dr. Robert Foster, the Company’s CEO, resigned from the Company as CEO and director for personal reasons, effective immediately.

Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the ...

Dr. Robert Foster, Hepion’s CEO, added “The antiviral, anti-cancer, and antifibrotic activities of rencofilstat address many of the most deadly and prevalent diseases affecting people today.

About Hepion Pharmaceuticals The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes.

In addition, Hepion’s AI/ML can be used to drive its ongoing NASH and HCC clinical development programs and identify other potential therapeutic indications for cyclophilin inhibition with ...

--Hepion Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on Artificial Intelligence- driven therapeutic drug development for the treatment of non-alcoholic ...

Aurinia has tamped down investor unrest, naming its former CEO Robert Foster to its board in an agreement with major stockholder MKT Capital.